Tevogen Bio (NASDAQ:TVGN) Announces Quarterly Earnings Results

Tevogen Bio (NASDAQ:TVGN) announced its quarterly earnings data on Friday. The company reported ($1.61) EPS for the quarter, beating the consensus estimate of ($2.00) by $0.39, FiscalAI reports.

Tevogen Bio Stock Performance

Tevogen Bio stock traded down $1.47 during mid-day trading on Friday, hitting $7.95. The company’s stock had a trading volume of 20,555 shares, compared to its average volume of 27,610. Tevogen Bio has a one year low of $4.14 and a one year high of $75.50. The company has a 50 day moving average of $6.33 and a 200-day moving average of $14.49.

Analyst Ratings Changes

Several equities analysts have commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research report on Monday, April 20th. Wall Street Zen downgraded Tevogen Bio to a “strong sell” rating in a research report on Saturday, March 21st. Finally, D. Boral Capital downgraded Tevogen Bio from a “buy” rating to a “hold” rating in a research report on Wednesday, March 4th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $100.00.

Hedge Funds Weigh In On Tevogen Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its position in shares of Tevogen Bio by 126.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after buying an additional 152,572 shares in the last quarter. Deutsche Bank AG grew its position in shares of Tevogen Bio by 304.1% during the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after buying an additional 130,738 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its position in shares of Tevogen Bio by 66.7% during the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after buying an additional 33,000 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.